Skip to main navigation
Contact Us
Careers
facebook
instagram
twitter
linkedin
Our Company
Who We Are
Leadership & Board
Patient Advocacy
Diversity, Equity, Inclusion & Belonging
Grant Programs
ISR Grants
Med Ed Grants
Contact Us
Careers
News
Our Science
Our Pipeline
Sparsentan for FSGS
Chenodeoxycholic Acid (CDCA) Program
Pegtibatinase
Alagille Syndrome Collaboration
Therapeutic Areas
IgA Nephropathy (IgAN)
Focal Segmental Glomerulosclerosis (FSGS)
Classical Homocystinuria (HCU)
Alagille Syndrome (ALGS)
Bile Acid Synthesis Disorders (BASD)
Cerebrotendinous Xanthomatosis (CTX)
Cystinuria
Peroxisome Biogenesis Disorder-Zellweger Spectrum Disorder (PBD-ZSD)
Clinical Trials
Expanded Access
Diagnostic Testing Programs
Our Therapies
Rare Life
Investors & Media
Press Releases
Events & Presentations
Leadership & Board
Governance Documents
SEC Filings
Quarterly Results
Stock Information
Historic Stock Lookup
Analyst Coverage
Investor Q&As
Contact Us
EVENT
DETAILS
Investor Relations
Press Releases
Events & Presentations
Leadership & Board
Governance Documents
SEC Filings
Quarterly Results
Stock Information
Investor Q&As
Contact Us
«
Back
Travere Therapeutics First Quarter Financial Results and Corporate Update
May 05, 2022 at 4:30 PM EDT
Listen to webcast
Print Page
Email Alerts
Download Library
RSS Feeds
Share
Search